372 related articles for article (PubMed ID: 9164316)
1. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study.
Lancet; 1997 May; 349(9063):1429-35. PubMed ID: 9164316
[TBL] [Abstract][Full Text] [Related]
2. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications.
Lincoff AM; Califf RM; Anderson KM; Weisman HF; Aguirre FV; Kleiman NS; Harrington RA; Topol EJ
J Am Coll Cardiol; 1997 Jul; 30(1):149-56. PubMed ID: 9207636
[TBL] [Abstract][Full Text] [Related]
3. Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Angiographic results from the CAPTURE trial.
van den Brand M; Laarman GJ; Steg PG; De Scheerder I; Heyndrickx G; Beatt K; Kootstra J; Simoons ML
Eur Heart J; 1999 Nov; 20(21):1572-8. PubMed ID: 10529325
[TBL] [Abstract][Full Text] [Related]
4. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group.
Simoons ML; de Boer MJ; van den Brand MJ; van Miltenburg AJ; Hoorntje JC; Heyndrickx GR; van der Wieken LR; de Bono D; Rutsch W; Schaible TF
Circulation; 1994 Feb; 89(2):596-603. PubMed ID: 7508826
[TBL] [Abstract][Full Text] [Related]
5. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.
Hamm CW; Heeschen C; Goldmann B; Vahanian A; Adgey J; Miguel CM; Rutsch W; Berger J; Kootstra J; Simoons ML
N Engl J Med; 1999 May; 340(21):1623-9. PubMed ID: 10341274
[TBL] [Abstract][Full Text] [Related]
6. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators.
Lefkovits J; Ivanhoe RJ; Califf RM; Bergelson BA; Anderson KM; Stoner GL; Weisman HF; Topol EJ
Am J Cardiol; 1996 May; 77(12):1045-51. PubMed ID: 8644655
[TBL] [Abstract][Full Text] [Related]
7. Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade.
Ghaffari S; Kereiakes DJ; Lincoff AM; Kelly TA; Timmis GC; Kleiman NS; Ferguson JJ; Miller DP; Califf RA; Topol EJ
Am J Cardiol; 1998 Jul; 82(1):7-12. PubMed ID: 9671000
[TBL] [Abstract][Full Text] [Related]
8. One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel.
Schömig A; Schmitt C; Dibra A; Mehilli J; Volmer C; Schühlen H; Dirschinger J; Dotzer F; ten Berg JM; Neumann FJ; Berger PB; Kastrati A;
Eur Heart J; 2005 Jul; 26(14):1379-84. PubMed ID: 15734767
[TBL] [Abstract][Full Text] [Related]
9. Elevated troponin T and C-reactive protein predict impaired outcome for 4 years in patients with refractory unstable angina, and troponin T predicts benefit of treatment with abciximab in combination with PTCA.
Lenderink T; Boersma E; Heeschen C; Vahanian A; de Boer MJ; Umans V; van den Brand MJ; Hamm CW; Simoons ML;
Eur Heart J; 2003 Jan; 24(1):77-85. PubMed ID: 12559939
[TBL] [Abstract][Full Text] [Related]
10. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
EPILOG Investigators
N Engl J Med; 1997 Jun; 336(24):1689-96. PubMed ID: 9182212
[TBL] [Abstract][Full Text] [Related]
11. Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial.
Marmur JD; Mitre CA; Barnathan E; Cavusoglu E
Am Heart J; 2006 Nov; 152(5):876-81. PubMed ID: 17070148
[TBL] [Abstract][Full Text] [Related]
12. Antiplatelet therapy in therapy-resistant unstable angina. A pilot study with REO PRO (c7E3).
van den Brand MJ; Simoons ML; de Boer MJ; van Miltenburg A; van der Wieken LR; de Feyter PJ
Eur Heart J; 1995 Nov; 16 Suppl L():36-42. PubMed ID: 8869017
[TBL] [Abstract][Full Text] [Related]
13. A risk-benefit assessment of abciximab in angioplasty.
Kleiman NS
Drug Saf; 1999 Jan; 20(1):43-57. PubMed ID: 9935276
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of the platelet glycoprotein IIb/IIIa inhibitor abciximab in Chinese patients undergoing high-risk angioplasty.
Chen YH; Chen JW; Wu TC; Ding PY; Wang SP; Chang MS
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jan; 63(1):8-15. PubMed ID: 10645045
[TBL] [Abstract][Full Text] [Related]
15. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty.
Wöhrle J; Grebe OC; Nusser T; Al-Khayer E; Schaible S; Kochs M; Hombach V; Höher M
Circulation; 2003 Apr; 107(14):1840-3. PubMed ID: 12682003
[TBL] [Abstract][Full Text] [Related]
16. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.
EPIC Investigators
N Engl J Med; 1994 Apr; 330(14):956-61. PubMed ID: 8121459
[TBL] [Abstract][Full Text] [Related]
17. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.
Stone GW; Grines CL; Cox DA; Garcia E; Tcheng JE; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Carroll JD; Rutherford BD; Lansky AJ;
N Engl J Med; 2002 Mar; 346(13):957-66. PubMed ID: 11919304
[TBL] [Abstract][Full Text] [Related]
18. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
Mehilli J; Kastrati A; Schühlen H; Dibra A; Dotzer F; von Beckerath N; Bollwein H; Pache J; Dirschinger J; Berger PP; Schömig A;
Circulation; 2004 Dec; 110(24):3627-35. PubMed ID: 15531766
[TBL] [Abstract][Full Text] [Related]
19. Laboratory monitoring of heparin and the combination of heparin and the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3) in patients undergoing percutaneous transluminal coronary angioplasty (PTCA).
Zahn R; Haubelt H; Bechtloff S; Schneider S; Frilling B; Rustige J; Marsalek P; Seidl K; Senges J; Hellstern P
Herz; 2003 Aug; 28(5):445-52. PubMed ID: 12928744
[TBL] [Abstract][Full Text] [Related]
20. Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC trial. Evaluation of c7E3 for the Prevention of Ischemic Complications.
Lefkovits J; Blankenship JC; Anderson KM; Stoner GL; Talley JD; Worley SJ; Weisman HF; Califf RM; Topol EJ
J Am Coll Cardiol; 1996 Oct; 28(4):849-55. PubMed ID: 8837559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
